Loading...
Market
What will be the total investment Sanofi makes in the Frankfurt insulin facility by 2029?
2
Resolution / Starting Odds
€1.3B or less • 25%
More than €1.3B to €1.5B • 25%
More than €1.5B to €1.7B • 25%
More than €1.7B • 25%
Official financial statements from Sanofi, press releases, and news articles
Story
Sanofi to Invest €1.3B in New BioCampus Frankfurt Insulin Facility by 2029
Aug 1, 2024, 06:28 PM
French drugmaker Sanofi has announced plans to invest 1.3 billion euros ($1.40 billion) in a new insulin production facility at its existing site in Frankfurt Höchst, Germany, part of the BioCampus. The new facility, expected to be completed by 2029, aims to enhance the production of Sanofi's insulin brand, Lantus. This investment is part of Sanofi's broader strategy to expand its manufacturing capacity, which includes a recent commitment of $1.1 billion to increase capacity at three sites in France. The new Frankfurt insulin plant is anticipated to create hundreds of jobs in Germany, adding to the site's current workforce of over 4,000 employees and over 500 jobs in France.
View original story
Similar markets
Construction started • 25%
Construction completed • 25%
Production started • 25%
None of the above • 25%
Less than 500 • 25%
500 to 1000 • 25%
1000 to 1500 • 25%
More than 1500 • 25%
Fully operational • 25%
Partially operational • 25%
Not operational • 25%
Other • 25%
Less than $25 billion • 25%
$25 billion to $30 billion • 25%
$30 billion to $35 billion • 25%
More than $35 billion • 25%
Increase by over 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change • 25%
Less than $4.5 billion • 25%
$4.5 billion to $5 billion • 25%
$5 billion to $5.5 billion • 25%
More than $5.5 billion • 25%
Improved relations • 25%
No change • 25%
Worsened relations • 25%
Other • 25%
None • 33%
1 to 2 • 33%
More than 2 • 34%